Latest Regulatory News

Encounter Resources Limited has unveiled an ambitious 2025 exploration and development program across its Australian critical minerals projects, supported by significant government co-funding and a strong cash position.

Vulcan Energy Resources has marked significant progress in Q1 2025 by achieving Strategic Project status under the EU Critical Raw Materials Act and producing Europe’s first fully integrated battery-quality lithium hydroxide monohydrate. The company advances drilling, financing, and commercial partnerships, positioning itself as a key player in Europe’s sustainable lithium supply chain.

Alchemy Resources Limited reported a modest net cash outflow in operating activities for Q1 2025 but ended the quarter with a robust cash balance supporting over 17 quarters of funding.

New Frontier Minerals has identified 46 priority exploration targets rich in heavy rare earth elements at its Harts Range Project and formalized a strategic alliance to process copper ore from its Big One Deposit, marking significant progress in its multi-commodity portfolio.

Asian Battery Metals PLC has completed an oversubscribed A$3.96 million capital raise, fully funding its expanded 2025 exploration program focused on the promising Oval Cu-Ni-PGE discovery in Mongolia. Phase 3 drilling is underway, targeting deeper and along-strike extensions, with initial assay results expected in May.

Peak Rare Earths made significant strides in the March 2025 quarter, progressing its Ngualla Rare Earth Project, securing A$8.5 million in capital, and benefiting from a surge in rare earth prices driven by growing EV demand and evolving Chinese regulations.

Bio-Gene Technology Limited has been awarded two significant grants totaling A$3 million by the US Department of Defense, validating its innovative insecticide technologies Flavocide® and Qcide®. The company is advancing regulatory filings and scaling production to target both military and civilian markets.

Antipa Minerals has consolidated its Paterson Province tenements into the expansive Minyari Project, resumed full ownership of Wilki and Paterson Projects following partner withdrawals, and launched a major drilling campaign targeting resource growth and new discoveries.

Argenica Therapeutics has completed patient dosing in its Phase 2 trial of ARG-007 for acute ischaemic stroke, with topline data expected in Q3 2025. The company also plans to submit its Investigational New Drug application and Fast Track request to the FDA imminently.

EMVision Medical Devices has commenced the pivotal clinical trial for its emu™ bedside brain scanner aimed at FDA clearance, while advancing its First Responder device through successful aeromedical testing and ethics approvals. The company maintains strong cash reserves of $12.58 million to support ongoing innovation and clinical activities.

Elevate Uranium Ltd reports steady progress on its U-pgrade demonstration plant and ongoing exploration drilling at Koppies and Marenica projects, alongside a 12% resource increase at the Bigrlyi Joint Venture and the appointment of a new chairman.

Cavalier Resources has signed a non-binding US$11 million streaming finance term sheet with Raptor International to fund the Stage 1 open pit development of its Crawford Gold Project, backed by a robust updated Pre-Feasibility Study.